alprazolam wh (alprazolam mylan) tafla 0,5 mg
williams & halls ehf - alprazolamum inn - tafla - 0,5 mg
baklofen viatris (baklofen mylan) tafla 10 mg
viatris limited - baclofenum inn - tafla - 10 mg
baklofen viatris (baklofen mylan) tafla 25 mg
viatris limited - baclofenum inn - tafla - 25 mg
naproxen viatris (naproxen mylan) tafla 250 mg
viatris limited - naproxenum inn - tafla - 250 mg
naproxen viatris (naproxen mylan) tafla 500 mg
viatris limited - naproxenum inn - tafla - 500 mg
tamsulosin viatris (tamsulosin mylan 0,4 mg hart hylki með breyttan losunarhraða) hart hylki með breyttan losunarhraða 0,4 mg
viatris limited - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg
atropin viatris (atropin mylan) stungulyf, lausn 0,5 mg/ml
viatris limited - atropine sulfate - stungulyf, lausn - 0,5 mg/ml
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Æxlishemjandi lyf - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
hyqvia
baxalta innovations gmbh - mönnum eðlilegt að notkun - Ónæmisfræðilegir skortsyndar - Ónæmiskerfið sera og mótefni, - skipti meðferð hjá fullorðnum, börn og unglingar (0-18 ár) í aðal ónæmisgalla heilkennum með skert mótefni framleiðslu. hypogammaglobulinaemia og endurtekin bakteríusýkingum í sjúklinga með langvarandi eitilfrumuhvítblæði (cll), í hvern fyrirbyggjandi sýklalyf hafa mistókst eða eru ætlað. hypogammaglobulinaemia og endurtekin bakteríusýkingum í margar forráðamenn (mm) sjúklingar. hypogammaglobulinaemia í sjúklingar fyrir og eftir ósamgena blóðmyndandi stafa klefi ígræðslu (hsct).
flebogamma dif (previously flebogammadif)
instituto grifols s.a. - mönnum eðlilegt að notkun - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - Ónæmiskerfið sera og mótefni, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.